AUROPHARMA2023-04-012023-06-30 AUROPHARMA2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2023-06-30 AUROPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AUROPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AUROPHARMA2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524804 AUROPHARMA NOTLISTED Aurobindo Pharma Limited Equity 2023-04-01 2024-03-31 2023-08-12 2023-08-03 INR Millions First quarter 15:30:00 17:40:00 2023-08-12 2023-08-12 Not applicable Single segment Pharmaceutical Products 2023-04-01 2023-06-30 Unaudited Consolidated 68505200000.00 1163300000.00 69668500000.00 27568300000.00 5801600000.00 -1822800000.00 9519700000.00 565500000.00 3265600000.00 15924700000.00 60822600000.00 8845900000.00 -697500000.00 8148400000.00 3404700000.00 -981500000.00 2423200000.00 0.00 5725200000.00 0.00 0.00 0.00 -28100000.00 5697100000.00 -303700000.00 5393400000.00 5707500000.00 -10400000.00 5403800000.00 -10400000.00 585900000.00 1 9.74 9.74 0.00 0.00 9.74 9.74 1. The above consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on Consolidated financial statements and Ind AS 28 on Investments in Associates and Joint ventures notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 12, 2023. The results for the quarter ended June 30, 2023 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2023. 4. During the current quarter, the Company announced that Auro PR Inc., a step-down wholly owned subsidiary based at Caguas, Puerto Rico, is undertaking restructuring of its facility to enhance production volume. The Group has accrued the severance pay due to the employees of Auro PR Inc., who are being retrenched owing to the said restructuring and disclosed the same as an exceptional item. Other Expenses 15924700000.00 Notes continued......... 5. The Group operates in only one reportable segment viz., 'Pharmaceutical Products'. 6. The Board of Directors of the Company at its meeting held on June 17, 2022 had approved investment in GLS Pharma Limited (GLS). Consequently the Company entered into share subscription and purchase agreement and obtained control (51%) w.e.f August 17, 2022. 7. During the current quarter, Auro Vaccines Private Limited (Wholly owned subsidiary) acquired equity shares of Tergene Biotech Limited (Joint Venture) from Aurobindo Pharma Limited (Parent). Consequently, Tergene Biotech Limited became a joint venture of Auro Vaccines Private Limited w.e.f April 1, 2023. 8. The figures for the quarter ended March 31, 2023 are the balancing figures of the audited financials for the year ended March 31, 2023 and unaudited the year to date published results for the nine months ended December 31, 2022, which were subject to limited review by the statutory auditors. Re-measurement of defined employee benefit liability 19600000.00 Equity investments through other comprehensive income – net change in fair value -27800000.00 -8200000.00 -11900000.00 Exchange differences on translating the financial statements of foreign operations -307400000.00 -307400000.00 0.00